Egetis Therapeutics AB

Update in progress

EGTX.ST (Stockholm)

Egetis Therapeutics AB (publ) is a pharmaceutical company focused on developing and commercializing orphan drugs in Sweden and abroad. It is advancing Aladote, in Phase IIb/III, to treat acetaminophen overdose and prevent acute liver failure, and Emcitate, in Phase IIb, for monocarboxylate transporter 8 deficiency. Formerly PledPharma AB, it adopted its current name in December 2020. Founded in 2006 and based in Stockholm.